The Beta-blocker to LOwer CArdiovascular Dialysis Events (BLOCADE) Feasibility Study

β-受体阻滞剂降低心血管透析事件 (BLOCADE) 可行性研究

• 批准号: nhmrc : 1006171
• 负责人: A/Pr Carmel Hawley
• 金额: $ 39.86万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2011
• 资助国家: 澳大利亚
• 起止时间: 2011-01-01 至 2015-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/beta-blocker-lower-feasibility-study/109151
• 关键词: Beta; blocker; LOwer; CArdiovascular; Dialysis

The BLOCADE Feasibility Study aims to find out what is needed for a study to see if the drug carvedilol reduces heart disease events in people who need kidney dialysis. Carvedilol is widely used to treat the types of heart disease that are common in people on dialysis but the nature of dialysis may lead to more side effects or to less benefit. A Feasibility Study must be done first to properly plan a large study of carvedilol in people on dialysis that answers this important question.

BLOCADE可行性研究旨在找出一项研究所需的条件，以确定药物卡维地洛是否能减少需要肾脏透析的人的心脏病事件。卡维地洛被广泛用于治疗透析患者常见的心脏病类型，但透析的性质可能导致更多的副作用或较少的益处。为了回答这个重要的问题，必须首先进行可行性研究，以正确地计划卡维地洛在透析患者中的大规模研究。